Skip to main content
SpringerLink
Log in

Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin’s lymphoma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Apoptosis-related proteins play an important role in lymphoma cell death during chemotherapy. In our study, we investigated the prognostic significance of CD95, BCL2, and P53 expression in extranodal non-Hodgkin’s lymphoma (NHL). We examined 71 patients with extranodal NHL [45 diffuse large B-cell lymphomas (DLBCLs) and 26 mucosa-associated lymphoid tissue lymphomas (MALTLs)], 35 male and 36 female, with a median age of 65.8 years. The most common site of origin was the stomach (N = 31). Paraffin-embedded specimens were analyzed immunohistochemically for CD95, BCL2, and P53 expression. Multivariate analysis revealed that in DLBCLs, positive CD95 and negative BCL2 expression were independent prognostic factors for overall survival. We reached the same conclusion for MALTLs, with positive CD95 and negative P53 expression. In DLBCLs, the 5-year overall survival rate was 71.5% for the CD95-positive cases and 35% for the CD95-negative cases (p = 0.004) and the 5-year overall survival was significantly better in BCL2-negative cases (70.8%) when compared to BCL2-positive cases (37%; p = 0.009). In MALTLs, the 5-year overall survival rate for the CD95-positive and CD95-negative groups was 89.5% and 42.9%, respectively (p = 0.004) and the 5-year overall survival rate was 50% for the P53-positive cases and 88.9% for the P53-negative cases (p = 0.016). In conclusion, positive CD95 expression proved to be a good prognostic factor of overall survival in both extranodal DLBCLs and MALTLs. In contrast, positive expression of BCL2 and P53 was found to be unfavorably associated with survival in extranodal DLBCLs and MALTLs, respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Feller AC, Diebold J (2004) Histopathology of nodal and extranodal non-Hodgkin’s lymphomas. 3rd, completely rev. and updated ed. Springer, Berlin, p 186

    Google Scholar 

  2. Irisarri M, Plumas J, Bonnefoix T et al (2000) Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin’s lymphoma B cell line. Leukemia 14:2149–2158

    Article  CAS  PubMed  Google Scholar 

  3. Troeger A, Glouchkova L, Escherich G et al (2008) Reduced expression of defective modulation of TNF receptor/ligand family molecules on proB-ALL blasts. Klin Pediatr 220:353–357

    Article  CAS  Google Scholar 

  4. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA (1996) CD95-induced apoptosis of lymphocytes in an immune-privileged cite induces immunological tolerance. Immunity 5:7–16

    Article  CAS  PubMed  Google Scholar 

  5. Landowski TH, Moscinski L, Burke R (2001) CD95 antigen mutations in hematopoietic malignancies (review). Leuk Lymphoma 42:835–846

    Article  CAS  PubMed  Google Scholar 

  6. Wilson WH, Teruya-Feldstein J, Fest T (1997) Relationship of P53, BCL2, and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas. Blood 89:601–609

    CAS  PubMed  Google Scholar 

  7. Harris SL, Levine AJ (2005) The P53 pathway: positive and negative feedback loops (review). Oncogene 24:2899–2908

    Article  CAS  PubMed  Google Scholar 

  8. Steele RJ, Lane DP (2005) P53 in cancer: a paradigm for modern management of cancer (review). Surg 3:197–205

    Article  CAS  Google Scholar 

  9. Kroemer G (1997) The proto-oncogene BCL2 and its role in regulating apoptosis. Nat Med 3:614–620

    Article  CAS  PubMed  Google Scholar 

  10. Chao DT, Korsmeyer SJ (1998) BCL-2 family: regulators of cell death. Annu Rev Immunol 16:395–419

    Article  CAS  PubMed  Google Scholar 

  11. Pazella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB et al (1993) BCL2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690–694

    Article  Google Scholar 

  12. Pazella F, Gatter K (1995) What is the value of BCL2 protein detection for histopathologists? Histopathology 26:89–93

    Article  Google Scholar 

  13. Wohlfart S, Sebinger D, Gruber P (2004) FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphomas DLBCL. Am J Pathol 164:1081–1089

    CAS  PubMed  Google Scholar 

  14. Imamura J, Miyoshi I, Koeffler HP (1994) P53 in hematologic malignancies. Blood 84:2412–2421

    CAS  PubMed  Google Scholar 

  15. Hernandez L, Fest T, Cazorla M et al (1996) P53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87:3351–3359

    CAS  PubMed  Google Scholar 

  16. Li Y, Raffo AJ, Drew L, Mao Y (2003) FAS-mediated apoptosis is dependent on wild-type P53 status in human cancer cells expressing a temperature-sensitive P53 mutant alanine-143. Cancer Res 63:1527–1533

    CAS  PubMed  Google Scholar 

  17. Das GC, Holiday D, Gallardo R, Haas C (2001) Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type P53 status and under isogenic condition. Cancer Lett 165:147–153

    Article  CAS  PubMed  Google Scholar 

  18. Stewart ZA, Tang LJ, Pietenpol JA (2001) Increased P53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 20:113–124

    Article  CAS  PubMed  Google Scholar 

  19. Makin G, Hickman JA (2000) Apoptosis and cancer chemotherapy. Cell Tissue Res 301:143–152

    Article  CAS  PubMed  Google Scholar 

  20. Piris MA, Pezella F, Martinez-Montero JC et al (1994) P53 and BCL2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 69:337–341

    CAS  PubMed  Google Scholar 

  21. Reed JC (1995) Regulation of apoptosis by BCL2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7:541–546

    Article  CAS  PubMed  Google Scholar 

  22. Hermine O, Haioun C, Lepage E (1996) Prognostic significance of BCL2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 87:265–272

    CAS  PubMed  Google Scholar 

  23. Miyashita T, Reed JC (1993) BCL2 oncoprotein blocks chemotherapyinduced apoptosis in a human leukemia cell line. Blood 81:151–157

    CAS  PubMed  Google Scholar 

  24. Iwai K, Miyawaki T, Takizawa T (1994) Differential expression of BCL2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 84:1201–1208

    CAS  PubMed  Google Scholar 

  25. Yoshino T, Kondo E, Cao L (1994) Inverse expression of BCL2 protein and FAS antigen in lympho-blasts in peripheral blood T and B lymphocytes. Blood 83:1856–1861

    CAS  PubMed  Google Scholar 

  26. Nguyen PL, Harris NL, Ritz J, Robertson MJ (1996) Expression of CD95 antigen and BCL2 protein in non Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol 148:847–853

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors gratefully acknowledge the collaboration of the technical staff of the Pathology Department.

Authorship and disclosures

AC was the principal investigator and analyzed the data. IV and NP participated in the scoring of immunohistochemical results. GT and GA participated in the statistical analysis.

Author information

Authors and Affiliations

  1. Pathology Department, Ippokration Hospital, 5 Zagoras st., 54636, Thessaloniki, Greece

    Anastasios Chatzitolios & Ioannis Venizelos

  2. Department of Histology-Embryology, Democritus University of Thrace, Alexandroupolis, Greece

    Gregory Tripsiannis, George Anastassopoulos & Nikolaos Papadopoulos

Authors
  1. Anastasios Chatzitolios
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ioannis Venizelos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory Tripsiannis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George Anastassopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nikolaos Papadopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anastasios Chatzitolios.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chatzitolios, A., Venizelos, I., Tripsiannis, G. et al. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin’s lymphoma. Ann Hematol 89, 889–896 (2010). https://doi.org/10.1007/s00277-010-0945-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-0945-x

Keywords

Search

Navigation